|
Active empiric therapy
|
31
|
28.2
|
|
Empiric antibiotics used (n = 129)
|
|
Piperacillin–tazobactam
|
29
|
23.6
|
|
Ceftriaxone
|
15
|
12.2
|
|
Cefuroxime
|
13
|
10.6
|
|
Meropenem
|
12
|
9.8
|
|
Ampicillin-sulbactam
|
12
|
9.8
|
|
Ciprofloxacin
|
8
|
6.5
|
|
Amoxicillin-clavulanate
|
6
|
4.9
|
|
Metronidazole
|
6
|
4.9
|
|
Ceftazidime
|
4
|
3.3
|
|
Vancomycin
|
4
|
3.3
|
|
Cefoperazone
|
4
|
3.3
|
|
Azithromycin
|
4
|
3.3
|
|
Imipenem
|
2
|
1.6
|
|
Trimethoprim/sulfamethoxazole
|
2
|
1.6
|
|
Clindamycin
|
1
|
0.8
|
|
Cefepime
|
1
|
0.8
|
|
Combination empiric therapy
|
15
|
13.6
|
|
Definitive antibiotics (n = 92)
|
|
Meropenem
|
74
|
80.4
|
|
Imipenem
|
9
|
9.8
|
|
Ciproflocaxin
|
4
|
4.3
|
|
Piperacillin–tazobactam
|
3
|
3.3
|
|
Trimethoprim/sulfamethoxazole
|
1
|
1.1
|
|
Ertapenem
|
1
|
1.1
|
|
Combination definitive therapy
|
6
|
5.5
|
|
Mean duration before active antibiotics
|
3.9 ± 2.7
| |
